
64Cu-SAR-bisPSMA gained FDA fast track status for advanced prostate cancer imaging.

Ira Zackon, MD, discusses what strategies community oncology practices can implement to address racial and socioeconomic disparities in chronic lymphocytic leukemia.

Nazli Dizman, MD, discusses the current accountability measures for enforcing the language of respect guidelines in renal cell carcinoma.

The FDA issued a complete response letter for linvoseltamab aimed at treating relapsed/refractory multiple myeloma post multiple therapies.

The VISTA-101 clinical trial is investigating KVA12123, a VISTA-blocking immunotherapy, in advanced solid tumors.

Jeff Sharman, MD, discusses the background of the ELEVATE-TN trial and its long-term efficacy data.

The application is supported by the phase 3 CheckMate -9DW study, and the FDA has set a target action date of April 21, 2025.

The US label for lenvatinib has been updated to include new clinical efficacy data for its use as a first-line treatment in advanced non-clear cell renal cell carcinoma, based on results from the KEYNOTE-B61 trial.

Backed by the phase 1 ARTEMIS-001 trial, the FDA has granted GSK5764227 a breakthrough therapy designation for the treatment of extensive-stage small cell lung cancer.

In an interview with Targeted Oncology, Hope S. Rugo, MD, FASCO, discussed data from the ELEVATE trial of elacestrant combinations in ER-positive/HER2-negative metastatic breast cancer.

Lazertinib and amivantamab as a first-line treatment for patients with locally advanced or metastatic non–small cell lung cancer with specific EGFR mutations demonstrated superior efficacy compared with standard treatment.

The FDA has lifted the partial clinical hold on the phase 1 YL202-INT-101-01 trial, allowing enrollment to resume in the US for patients with advanced NSCLC harboring EGFR mutations and HR-positive/HER2-negative breast cancer.

In an interview with Targeted Oncology, Evandro D. Bezerra, MD, discussed the real-world effectiveness of brexu-cel for relapsed/refractory B-cell acute lymphocytic leukemia.

In an interview with Targeted Oncology, Aristotelis Tsirigos, PhD, discussed a study evaluating a self-taught artificial intelligence tool that can accurately diagnose cases of adenocarcinoma.

PT217 has received an orphan drug designation from the FDA for the treatment of patients with neuroendocrine carcinoma.

The breakthrough therapy designation is supported by findings from the phase 3 DESTINY-Breast06 study comparing the antibody-drug conjugate with chemotherapy in patients with HR+/HER2-low breast cancer.

Apalutamide offers a quicker, deeper PSA response vs enzalutamide in mCSPC and the SENTRY study supports SOC combination therapy for myelofibrosis. We also cover integrative oncology, which has been shown to reduce cancer-related anxiety and depression and we explore vorasidenib’s FDA approval in glioma treatment.

In an interview with Targeted Oncology, Evandro D. Bezerra, MD, discusses brexucabtagene autoleucel for relapsed/refractory B-cell ALL.

The ON-SITE study has enrolled its first patient to evaluate an AI-based image analysis module for lung cancer.

In an interview with Targeted Oncology, Regina Barragan-Carrillo, MD, discussed the goals of a study evaluating camu camu with ipilimumab and nivolumab for treating metastatic renal cell carcinoma.

Mikkael A. Sekeres MD, MS, discusses the primary differences between imetelstat and other treatments available for patients with low- to intermediate-1 risk myelodysplastic syndromes.

The phase 3 inMIND trial evaluating tafasitamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma showed promising progression-free survival findings, according to topline results.

In an interview, Amrita Krishnan, MD, discussed several key advancements and challenges in the field of multiple myeloma.

A Prescription Drug User Fee Act target action date of February 17, 2025, has been set for a decision on the vimseltinib application.

The FDA has given positive feedback on the planned phase 3 study for the combination of amezalpat, atezolizumab, and bevacizumab in the first-line treatment of unresectable or metastatic hepatocellular carcinoma.

The FDA-approved regimen is for neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resectable non–small cell lung cancer.

Findings from the phase 3 E1910 study showed that blinatumomab extended overall survival when added to chemotherapy vs chemotherapy alone in B-cell precursor acute lymphoblastic leukemia.

A new drug application has been submitted to the FDA for UGN-102, an intravesical solution for treating low-grade, intermediate-risk non–muscle-invasive bladder cancer.

In this episode of Targeted Talks, Edwin Choy, MD, PhD, discussed the FDA approval of afamitresgene autoleucel for the treatment of patients with advanced synovial sarcoma.

Following promising data from the phase 1 Deltacel-01 trial, the FDA has given Deltacel plus low-dose radiation therapy a fast track designation in stage IV non–small cell lung cancer.